Three-dimensional ridge augmentation with xenograft and recombinant human platelet-derived growth factor-BB in humans: report of two cases.
The present paper reports on two patients who underwent three-dimensional ridge augmentation using a xenograft in combination with recombinant human platelet-derived growth factor-BB (rhPDGF-BB). Patient 1 received a deproteinized bovine block infused with PDGF and secured to the alveolar crest by two fixation screws to augment the crest horizontally. After 5 months, implants were successfully placed. Patient 2 underwent a vertical ridge augmentation procedure that combined deproteinized bovine bone particles embedded in a collagen matrix soaked in PDGF Three titanium dental implants were placed in each patient 5 months later. Clinical and histologic results showed excellent soft and hard tissue healing. Bone had regenerated throughout the whole area and the xenograft particles were embedded in bone, which presented resorption lacunae close to areas with ongoing bone formation. This indicated that, in augmented areas, intense physiologic remodeling was ongoing. No data exist concerning three-dimensional bone augmentation using PDGF and a xenograft in humans. This report suggests that the use of rhPDGF-BB in combination with a deproteinized bovine graft may have the potential to regenerate large three-dimensional alveolar defects in humans.
Simion
Massimo
M
Department of Periodontology, Institute for Dental Research and Education, University of Milan, Italy. msimion@studiosimion.it
Rocchietta
Isabella
I
Dellavia
Claudia
C
D000368:Aged; D000539:Alveolar Process / Q000033:anatomy & histology / Q000601:surgery*; D000540:Alveolar Ridge Augmentation / Q000379:methods*; D043925:Angiogenesis Inducing Agents / Q000627:therapeutic use*; D000818:Animals; D000077214:Becaplermin; D001861:Bone Regeneration; D002417:Cattle; D003758:Dental Implantation, Endosseous / Q000379:methods; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010982:Platelet-Derived Growth Factor / Q000627:therapeutic use*; D020574:Proto-Oncogene Proteins c-sis; D014183:Transplantation, Heterologous / Q000379:methods*
D043925:Angiogenesis Inducing Agents; D010982:Platelet-Derived Growth Factor; D020574:Proto-Oncogene Proteins c-sis; D000077214:Becaplermin